News

  • August 5, 2021
Verseon Nominates VE-4840 as Primary Drug Candidate for Oral Prophylaxis and Treatment of Diabetic Eye Disease
  • May 5, 2021
Verseon Diabetic Retinopathy Program Successfully Passes Important in vivo Test of Drug Efficacy
  • January 12, 2021
Verseon Receives European Patent for Innovative Thrombin Inhibitors
  • November 30, 2020
Trevor M. Jones Joins Verseon’s Scientific Advisory Board
  • September 30, 2020
Verseon Announces its Third Program Targeting Cancer
  • April 20, 2020
Verseon Publishes Efficacy Data on Anticoagulant VE-1902 in the Journal Thrombosis Research
  • February 24, 2020
Frank Doyle Joins Verseon’s Scientific Advisory Board